Bill Sibold – Executive Vice President, Sanofi Genzyme

Speaking exclusively to PharmaBoardroom, Sanofi Genzyme Executive VP Bill Sibold outlines Sanofi’s strategy for its specialty care unit, the wealth of potential breakthrough assets in its pipeline, product launch strategies, and the post-COVID industry of tomorrow.  
Since I joined in 2011, it feels as if my time with Sanofi Genzyme has been one constant, giant launch! ...the fundamental challenge but also opportunity in specialty care is the need to understand the challenges and priorities of the individual patient and physician communities
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report